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Abstract
Background:  Sharing of raw research data is common in many areas of medical research,
genomics being perhaps the most well-known example. In the clinical trial community investigators
routinely refuse to share raw data from a randomized trial without giving a reason.
Discussion: Data sharing benefits numerous research-related activities: reproducing analyses;
testing secondary hypotheses; developing and evaluating novel statistical methods; teaching; aiding
design of future trials; meta-analysis; and, possibly, preventing error, fraud and selective reporting.
Clinical trialists, however, sometimes appear overly concerned with being scooped and with
misrepresentation of their work. Both possibilities can be avoided with simple measures such as
inclusion of the original trialists as co-authors on any publication resulting from data sharing.
Moreover, if we treat any data set as belonging to the patients who comprise it, rather than the
investigators, such concerns fall away.
Conclusion:  Technological developments, particularly the Internet, have made data sharing
generally a trivial logistical problem. Data sharing should come to be seen as an inherent part of
conducting a randomized trial, similar to the way in which we consider ethical review and
publication of study results. Journals and funding bodies should insist that trialists make raw data
available, for example, by publishing data on the Web. If the clinical trial community continues to
fail with respect to data sharing, we will only strengthen the public perception that we do clinical
trials to benefit ourselves, not our patients.
Introduction
Investigators routinely refuse to share raw data from ran-
domized trials without giving a reason. In this paper, I will
argue that attitudes towards data sharing in the clinical
trial community need to rethought, drastically. I will start
by sharing some personal experiences of data sharing.
Data sharing anecdote 1: data to help plan a phase II trial
I was asked to help design an uncontrolled Phase II trial.
The idea was to treat a small cohort of patients and, if the
results looked promising, then design a large, randomized
trial to find out for sure if the treatment was of benefit. To
know whether "results looked promising" we needed
some idea of how patients would do in the absence of
treatment. We found a randomized, placebo-controlled
trial accruing a similar group of patients to those we
planned to study. We contacted the authors asking if we
could obtain part of the raw data from their trial: a list of
pre-treatment and follow-up scores for the control arm.
Given that the principal investigator (PI) worked at the
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National Institutes of Health (NIH), and that the study
was federally funded, we were therefore somewhat sur-
prised when he wrote back a short note stating: "We are
not prepared to release the data at this point."
Data sharing anecdote 2: data for a meta-analysis
I faced a problem when conducting a meta-analysis: some
trial reports had given summary data for number of events
per patient, others had given the proportion of patients
who were event-free. I wrote to the PI of one study asking
for raw data so that I could convert from event numbers
to event incidence. To her credit she said that she "would
love to share the data" – this was again a federally funded
study at the NIH – however, she was unable to do so
because "my biostatistician won't release it".
Data sharing anecdote 3: data to test a novel statistical 
method
I developed a novel statistical method with a colleague at
Memorial Sloan-Kettering Cancer Center (MSKCC). We
needed a data set on which to test our method and
thought that one of the large randomized trials conducted
by the cancer co-operative groups might be appropriate.
We approached an MSKCC physician who had a senior
position in one of these groups. After an extended discus-
sion, he eventually allowed us to present our ideas to the
appropriate committee. This involved a subsequent 45
minute telephone conference during which we pointed
out that: a) the results of our analysis had no clinical
implications and were of interest purely to statisticians; b)
we would stress this point in any paper; c) that the co-
operative group would be sent any paper before submis-
sion and would have full veto power. After a good deal of
deliberation, the committee finally relented ... to let us
present a written proposal. To this we heard no reply.
Data sharing anecdote 4: data to predict the effects of a 
drug
A large chemoprevention trial was published suggesting
that a widely used drug could help prevent a common
cancer. A colleague, who knew the investigators, pointed
out that the researchers had measured a certain biomarker
at baseline. We have previously shown that this biomarker
could predict occurrence of the cancer. My colleague
therefore proposed to the trial investigators that we col-
laborate on a study to determine whether the biomarker
could be used to predict response to the study drug. The
plan was that they would release the raw data to me, I
would build a statistical model and the two research
groups would jointly write a paper. Our proposal was
rejected.
Data sharing anecdote 5: data to predict the effects of 
surgery
A randomized trial was published showing clear benefits
of a certain type of cancer surgery. As it happens, the PI
was a good friend of a close colleague of mine. I suggested
to my colleague that we obtain raw data from the trial to
see if we could identify which patients would benefit most
from surgery. This was relatively straightforward: he asked
his friend, his friend said yes. But the PI failed to get
approval from the co-investigators and we never received
the raw data.
Data sharing anecdote 6: a positive story
I have also had several positive experiences of data shar-
ing: one example will suffice here. I proposed to Doug Alt-
man, who has written many of the popular Statistics Notes
articles for the British Medical Journal, that we write a Sta-
tistics Note on analysis of covariance (ANCOVA). He
thought that this was a good idea but recommended we
obtain a data set to illustrate our approach. I had become
friendly with Konrad Streitberger at a conference, so I
emailed him asking for raw data from a recently published
study, and he sent me back an Excel spreadsheet, pretty
much by return email. The Statistics Notes paper was pub-
lished with Streitberger's data [1]. Interestingly, we were
subsequently contacted by numerous statisticians who
wanted to use the data for teaching purposes.
To share or not to share: guilty until proven innocent
I was never given an explicit reason why any of my
requests to obtain raw data were rejected, so I can only
speculate. It might be that the investigators were afraid
that I might publish something that would misrepresent
their findings. If so, sharing of raw data is hardly the issue:
commentaries and review articles relying purely on a
trial's published results are often mistaken – indeed, one
article discussing the results of a surgery trial similar to
that discussed in anecdote 5 stated, wholly inaccurately,
that patients had died as a result of surgery[2] – and it
seems more likely that raw data would improve subse-
quent commentary. Moreover, in three of the four cases
where we planned to publish data, trialists were either
invited to be co-authors or were offered the opportunity
to read, revise and, if necessary, veto papers before sub-
mission. Alternatively, it might be that the trialists did not
want to be scooped by their own data. Yet suggestions for
collaborative publications were rejected and, moreover, I
am not aware that any of the groups we have approached
have published papers addressing the questions that inter-
ested us. It might be also be argued that the dispropor-
tionate fear of being scooped suggests that investigators
might be overly concerned with their careers in compari-
son to the value of research to patients.Trials 2006, 7:15 http://www.trialsjournal.com/content/7/1/15
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Whatever the reason, it is clear that there is a burden of
proof problem here: "no data sharing until there is clear
and unambiguous proof that no harm will result (espe-
cially to me)", rather than, "we should share data unless
we have some good reason to believe that this is not in the
best interests of patients." There appeared little recogni-
tion that producers of data are part of a community with
reciprocal obligations, or that all science builds on previ-
ous science (untold thousands of hours of brilliant scien-
tific work were required just to allow me to type this paper
on my laptop). Moreover, there did not seem to be any
appreciation that sharing of raw data may lead to tech-
niques or findings or further research that could help alle-
viate human distress (appendix 1). The general discourse
was, instead, "this is my data set, why should I let you
have it?"
Kirwan has undertaken a more systematic study of atti-
tudes about data sharing by surveying pharmaceutical
researchers [3]. In line with my somewhat frustrating
experiences, he reports that about three out of four
researchers, as well as an industry group, were opposed to
making raw data available from trials after publication.
What is of particular interest is that Kirwan documents the
reasons given by researchers against data sharing and pro-
vides a convincing riposte to each. For example, the most
common argument given against data sharing was that
analytical methods are pre-specified in study protocols
and it is inappropriate to use other methods; in particular,
an investigator analyzing shared data may engage in
"data-dredging" or choose invalid forms of analysis. Kir-
wan argues that it is for the scientific community as a
whole, not for individual trialists, to judge the suitability
of any reanalysis. Note also that in the data sharing anec-
dotes above, the analyses I planned were entirely inciden-
tal to the main purposes of a trial and hence could not
possibly have been pre-specified in the study protocol. Yet
they hardly seem like data-dredging. Kirwan reports and
rejects several additional arguments such as "difficulty of
extracting data relating to a particular publication" (this
must have been done for the data to have been analyzed);
costs of administering a database (a concern for the
appropriate website, not the trialists) and "an alternative
analysis may itself be commercially important". This last
point is particular interesting: Kirwan argues that if the
value of an alternative analysis is recognized by the phar-
maceutical company, it should be conducted before pub-
lication of the study results, if not, "then all the more
reason for ensuring that others in the field are in a posi-
tion to identify the need for and conduct the analysis".
Whose data set is it anyway?
In 2004, I published as PI a large study of acupuncture for
the treatment of chronic headache disorders [4]. At my
behest, 401 patients completed numerous questionnaires
over the course of a year, sometimes completing pain
scores four times a day for weeks at a time. Is this data set
mine? Or does it really belong to the patients in the trial,
and do I act merely as custodian? Several of the trials
described in the anecdotes above were literally life and
death: each of the steps on the survival curve was some-
one's daughter, someone's father, someone's wife. And yet
details of that death suddenly became a publicly-funded
researcher's private property.
In the USA at least, the data legally belong to trialists on
the grounds that it requires work to create knowledge
from data. But science, particularly medical science, is
essentially an enterprise conducted for moral reasons. We
need to do not just what is legal but what is right. As such,
we must take into account the probable wishes of the
patients who give us their blood, fill in our questionnaires
and die on our trials. It is difficult to believe that any
patient on my trial, who completed complex question-
naires so diligently over such a long period of time, would
really have wanted me to keep the data for myself rather
than share it with others for the benefit of medical science
in general.
How to share data
In many cases, sharing raw data is very straightforward,
here I'll do it right now: click the link for Additional File 1
to see a full data set from the acupuncture for headache
trial. It did not take me particularly long to create this file.
I needed to have a clean, well-annotated data set anyway
in order to conduct the statistical analyses for the trial
publication and so all that was required was to delete
some extraneous variables, convert to Microsoft Excel, and
write a few comments describing the data set. These com-
ments could be very short as I could refer to the published
trial for experimental details.
There are certain responsibilities I have as the producer of
the data. First, I have to make sure my data set is clean,
accurate and well-annotated, though this is good statisti-
cal practice anyway. Second, I have to make sure that I
have protected patient confidentiality. This is not just a
matter of deleting names and addresses, as identity can
conceivably be constructed from other data, such as date
of death, diagnosis and zip code (see published guidelines
for help [5]). By the same token, however, anonymizing
or "de-identifying" data is not particularly time consum-
ing. Third, I have the responsibility of deciding the appro-
priate level of detail for a data set. For example, in the
acupuncture trial, patients were given the SF-36 quality of
life questionnaire on three occasions. This instrument
consists of 36 questions that are summarized in 9
domains. In creating the data set, I decided not to give the
responses to each question as this would require over 100Trials 2006, 7:15 http://www.trialsjournal.com/content/7/1/15
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variables, rather I give the domain scores at each follow-
up time.
A researcher wishing to use raw data from a randomized
trial also has responsibilities. The most obvious is that the
source of the data must be cited. This is comparable to the
use of reference lists in papers to cite sources of published
data. Second, researchers have a responsibility to involve
the producers of the data set. Trialists have a deep knowl-
edge of the data and their expertise and advice can be
essential to avoid inappropriate analyses. As a general
rule, trialists should be invited to be collaborators on any
non-trivial novel research resulting from their data, with
full co-authorship on any resulting publication.
For more thoughts on the logistics of data sharing see the
datasharing.net website [6]; Appendix 1 summarizes the
benefits of sharing data from randomized trials: this
builds on earlier work by Hutchon [7].
Protecting the interests of trialists
It is not implausible that a trialist's reputation or career
could be harmed by data sharing. For example, what if a
researcher downloaded the data set from my acupuncture
trial, conducted an inappropriate analysis and then pub-
lished a paper showing how the new findings "refuted"
my conclusions? Similarly, if I planned a secondary anal-
ysis of my data, but was beaten to it by another researcher,
I would lose the opportunity to publish a paper, and
papers are, of course, the currency of a scientific career. In
appendix 2, I outline some guidelines for data sharing that
serve the dual function of protecting investigators and
optimizing the scientific value of trials. Appendix 2 might
be seen as a first attempt to answer Eysenbach and Sa's call
for a "code of conduct" for publication of raw data [8].
Two features of the guidelines are of particular interest.
First, they ensure that trialists are either co-authors on any
subsequent analyses for publication or are mandated a
published commentary along with the new analysis.
Moreover, trialists are guaranteed by the guidelines to be
the first to publish an analysis: they are not required to
publish or share any data which, in good faith, they plan
to analyze for further papers. To give a concrete example,
I am currently involved in the planning of a cancer trial in
which various biomarkers will be taken at baseline. I
expect that we will first publish the overall results of the
trial – cancer-free survival in each group – and later sub-
mit a series of papers looking at questions such as whether
the biomarkers predict either survival or response to the
study intervention. I do not think there is any need to
make available raw data on the biomarkers until we pub-
lish papers describing our biomarker analyses.
Nonetheless, I have little doubt that guidelines will not
always be followed and, even if they are, harm may still
occasionally result from publication or sharing of raw
data. I think we have to accept that harm will result from
any policy. The key question whether the benefits from
greater sharing of raw clinical trial data outweighs these
harms (in my view, this is far from a close call). We also
have to consider whether restricting the free flow of scien-
tific information to avoid rare adverse events is really what
we want as a research community.
Conclusion
The NIH currently requires that grants of $500,000 or
more per year provide a "data-sharing plan" in the grant
application [9]. Although this is a good start, it does not
ensure that data are indeed ultimately made available.
Moreover, only a fraction of randomized trials are NIH-
funded to the tune of $500,000 per year. My personal
solution would be to make it illegal to experiment on
humans and then fail to publish raw data within an
appropriate period of time. I assume there may be special
circumstances in which it might be reasonable to keep
data confidential – for example, during early phase devel-
opment of a patented drug – and one might envisage that
exceptions might be granted. Lest my proposal seem
rather draconian, consider whether some of the Vioxx-
related deaths might have been avoided had Merck been
forced to publish raw data on individual patients.
Pending the somewhat unlikely implementation of such
legislation, one starting point might be the journals: what
if journals, and Trials  would be a good starting place,
insisted that researchers submitted raw data, along with
the journal manuscript, for publication on the journal
website? I am not the first to make such a suggestion
[7,10]. Adding raw data submission to the host of other
requirements (conflict of interest, suggested reviewers,
copyright transfer etc.) hardly seems burdensome. Indeed,
trialists would merely be following the lead of genome
researchers where "all scholarly scientific journals should
now require the submission of microarray data to public
repositories as part of the process of publication" [11]. We
could also go to the funding agencies (NIH, Medical
Research Council, Wellcome) and suggest they demand
publication of raw data from randomized trials, in exactly
the same manner that they now require Open Access pub-
lication.
The editors of Trials have written that they "encourage
authors to make available all (or some of) the raw data
from the trials" [12] A voluntary code of this nature does
not seem to work. Eysenbach and Sa report that although
the Journal of Medical Internet Research explicitly invites
authors to attach raw data, none did so during the first
two years of publication [8].Trials 2006, 7:15 http://www.trialsjournal.com/content/7/1/15
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So perhaps what we need above all is a fundamental
change of attitudes within the clinical trial community.
Data sharing is common in other areas of science,
genomic research being the obvious example. I cannot
believe that it is unreasonable to ask clinical trialists to
share data when, say, yeast researchers do it routinely.
Let's make sharing of raw data a commonplace, natural
part of the clinical trials process, in the same way that we
view obtaining ethical approval or publication of the trial
results. If we fail to do so, we will only strengthen the pub-
lic perception that we do clinical trials to benefit our-
selves, not our patients.
Postscript
If you have any personal anecdotes about sharing of data
from randomized trials, please post a comment to this
paper or email me at vickersa@mskcc.org. Perhaps more
importantly, if you are a trialist and have some data that
you do not want to share, think you are justified in this
and believe your rationale is not covered in my guidelines,
please let me know: I want to make sure that we develop
a framework that meets everyone's needs.
Appendix 1. Benefits of sharing raw data from 
randomized trials
• Analyses can be reproduced and checked by others
• Acts as an additional incentive for checking that a data
set is clean and accurate
• Teaching
• Aids development and evaluation of novel statistical
methods
• Allows testing of secondary hypotheses
• Aids design of future trials
• Simplifies data acquisition for meta-analysis
• May help prevent fraud and selective reporting
Appendix 2. Suggested code of conduct for 
analysis of published raw data
Terminology: the "trialists" are the authors of a published
report of a randomized trial; "independent investigators"
are a separate group of researchers who wish to analyze
the raw trial data ("new analysis")
Code of conduct for independent investigators and 
journals
1. Independent investigators planning to publish a new
analysis should contact the trialists before undertaking
any analyses
2. One or more trialists should be offered a co-authorship
on any resulting papers
3. If trialists disagree with the methods or conclusions of
a new analysis:
a. They should not have veto power, unless this was
agreed beforehand by the independent investigators
b. They should, however, be guaranteed the opportu-
nity to write a commentary to be published alongside
the new analysis
4. Journals should not publish new analyses of previously
published data unless either a trialist is an author or a sep-
arate commentary from a trialist is attached
5. Published new analyses should cite the original trial
Code of conduct for trialists
1. Trialists must ensure that the data set is clean and well
annotated
2. Trialists must ensure that no individual patient could
be identified from the data set
3. Trialists should be required to share or publish immedi-
ately only those data associated with the main analyses of
a published trial
a. There is no need to share data required for planned
secondary analyses (e.g. correlative studies) although
trialists should in good faith restrict data sharing only
for analyses that they have concrete plans to publish
b. Regardless of any plans for future analyses, all raw
data should be published or made available for shar-
ing no longer than five years after first publication of
trial results
c. There is no need to update data (e.g. as deaths accrue
in a cancer trial)
4. Trialists must share all and any data requested if analy-
ses are not to be published (e.g. data required to aid trial
design)
Additional material
Additional File 1
Data set from acupuncture headache trial.
Data set from acupuncture headache trial
Click here for filePublish with BioMed Central    and   every 
scientist can read your work free of charge
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